Q&A: FDA medical policy chief talks decentralized trial guidance, improving diversity
The FDA’s director of its Office of Medical Policy wants trial sponsors to keep participant experiences top-of-mind in their decentralized designs.
Endpoints News sat down …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.